跳至主要内容
临床试验/NCT05423327
NCT05423327终止不适用

Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH)

Regeneron Pharmaceuticals95 个研究点 分布在 5 个国家目标入组 5,311 人开始时间: 2021年12月9日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
5,311
试验地点
95
主要终点
Genotype frequencies of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3)

研究概览

简要总结

Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • One or more of the following:
  • A prior diagnosis of NASH with a Clinical Research Network (CRN) fibrosis score of F1 to F4 based on liver biopsy
  • Evidence of NAFLD by imaging or liver histology as described in the protocol
  • The possible imaging modalities to assess historic evidence of NAFLD may be based on thresholds as described in the protocol
  • Known high-risk genotype for HSD17B13 (T/T or T/TA) and/or PNPLA3 (C/G,or G/G)
  • A clinical suspicion of NASH based on presence of 2 or more elements of the metabolic syndrome defined by:
  • Waistline that measures >35 inches (89 centimeters) for women or >40 inches (102 centimeters) for men
  • Historic fasting triglycerides >150 mg/dL within the prior 6 months
  • Historic fasting HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or on cholesterol-lowering medication within the prior 6 months
  • Historic fasting blood glucose >100 mg/dL or on diabetes medication within the prior 6 months
  • Historic blood pressure >130/85 mmHg, or on anti-hypertensive medication within the prior 6 months

排除标准

  • Known history or clinical evidence of drug abuse, within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms.
  • Excessive alcohol intake for ≥3 months during the past year prior to screening (>3 units/day for males and >2 units/day for females is generally considered excessive (unit: 1 glass of wine [approximately 125 mL]=1 measure of spirits [approximately 1 fluid ounce]=½ pint of beer [approximately 284 mL]).
  • History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score >
  • History of viral and resolved hepatitis or human immunodeficiency virus (HIV).
  • Any malignancy within the past 5 years except for basal cell or squamous epithelial cell carcinoma of the skin, or any carcinoma in situ.
  • Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

结局指标

主要结局

Genotype frequencies of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3)

时间窗: Day 1

Genotype frequencies of rs72613567 in Hydroxysteroid 17β dehydrogenase 13 (HSD17B13)

时间窗: Day 1

次要结局

  • Distribution of fibrosis-4 (FIB-4) scores across participants with different genotypes of rs72613567 in HSD17B13(Day 1)
  • Distribution of FIB-4 scores across participants with different genotypes of rs738409 in PNPLA3B13(Day 1)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (95)

Loading locations...

相似试验